What Is Geographic Atrophy?
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD). It happens when cells in the macula — the small area at the center of the retina that gives you sharp, detailed vision — gradually break down. Over time, patches of the macula thin out and stop working.
The name comes from the way those patches look to an eye doctor: distinct areas, like shapes on a map. "Atrophy" simply means tissue has worn away.
GA is sometimes called "advanced dry AMD." It is different from wet AMD, which involves abnormal blood vessels leaking under the retina.
How GA Affects Vision
The macula is what you use to read, recognize faces, drive, and see fine detail. When GA develops, people often notice:
- Blurriness or missing spots in the center of their vision
- Difficulty reading, especially small print or in low light
- Trouble recognizing faces
- Colors looking washed out or less vivid
- Needing more light to see clearly
GA usually affects both eyes, though one eye may be further along than the other. It does not cause total blindness, because side (peripheral) vision is generally kept. But losing central vision can make everyday tasks like reading, cooking, or driving much harder.
GA typically progresses slowly, over years. How quickly it moves varies a great deal from person to person.
Who Is at Risk
Age is the biggest risk factor — GA is most common in people over 60. Other factors include:
- A family history of AMD
- Smoking, or a history of smoking
- Light-colored eyes
- Heart disease, high blood pressure, or high cholesterol
- Long-term sun exposure without eye protection
Having dry AMD does not mean you will develop GA. Many people with earlier dry AMD never reach the advanced stage.
How GA Is Diagnosed
There is no blood test for GA. An eye doctor (ophthalmologist or retina specialist) diagnoses it during a dilated eye exam by looking at the retina. They may also use imaging:
- Optical coherence tomography (OCT) — a quick scan that shows the layers of the retina
- Fundus autofluorescence (FAF) — a photograph that highlights areas of the retina that are losing function
- Fluorescein angiography — a dye test used mainly to rule out wet AMD
Because early GA can be easy to miss, regular dilated eye exams matter, especially after age 50 or if AMD runs in your family.
What Can Be Done Today
GA has no cure, and there is no way to restore retina cells that have been lost. Current care focuses on slowing progression and helping people keep doing the things they care about.
Depending on your situation, your eye doctor may discuss:
- Nutrition — a specific vitamin and mineral formula studied in AMD research may lower the risk of progression to advanced AMD in some people. Ask your doctor whether it fits your eyes and health history, since some ingredients are not right for everyone.
- Smoking cessation — the single most useful change for people who smoke.
- Monitoring — checking your vision regularly at home and keeping follow-up appointments, so any change is caught early.
- Low vision support — magnifiers, brighter lighting, large-print or audio formats, and training from a low vision specialist can help considerably.
- Treatments under study — several approaches aimed at slowing GA growth are in clinical research.
Where Clinical Trials Fit In
Clinical trials are how new approaches for GA get tested. Some studies look at whether a treatment slows the growth of atrophy; others focus on vision, quality of life, or better ways to detect change over time.
If you are considering a GA study, it helps to understand what participation usually involves:
- Regular imaging — OCT and other scans at scheduled visits to track the retina
- Eye exams — visual acuity testing, dilated exams, and sometimes visual field testing
- Study treatment or placebo — depending on the design, participants may receive the study treatment through an injection into the eye (intravitreal injection), or may be assigned to a comparison group
- Time commitment — often a year or more, with visits every few weeks to a few months
- Travel and compensation — many studies cover or reimburse study-related costs; details vary by study
Choosing to join a study is always voluntary, and you can ask questions at any point before or during participation. Your regular eye care continues either way.
PRIME Trials is currently enrolling a study evaluating a one-time injection for geographic atrophy due to dry AMD of the eye. You can see the study details, eligibility information, and compensation on our studies page, or call or text us at (281) 220-9306 to speak with a study coordinator.
Questions Worth Asking Your Eye Doctor
- Do my scans show geographic atrophy, or earlier dry AMD?
- Where is the atrophy located, and how is it affecting my central vision?
- How often should I be monitored?
- Are there steps I can take that make sense for my eyes and health history?
- Would a clinical trial be a reasonable option for me to consider?
The Bottom Line
Geographic atrophy is a slow, progressive form of advanced dry AMD that affects central vision. It cannot be reversed today, but monitoring, supportive care, and research all play a part — and studies are actively looking for better options.
This article is general education and is not medical advice. It is not a substitute for an examination or recommendation from your eye doctor. Talk with your physician or retina specialist about your own eyes and care.
Sources: National Eye Institute — Age-Related Macular Degeneration; American Academy of Ophthalmology — What Is Geographic Atrophy?
